嵌合抗原受体
免疫疗法
医学
癌症
放射治疗
癌症治疗
乐观 主义
化疗
癌症治疗
细胞疗法
重症监护医学
细胞
内科学
生物
心理学
心理治疗师
遗传学
作者
Amir Hossein Barjasteh,Mostafa Saebi,Mahmoud Mahmoudi,Ramiar Kamal Kheder,Seyed Isaac Hashemy,Fatemeh Forouzanfar,Seyed‐Alireza Esmaeili
标识
DOI:10.2174/0113816128336391241107112957
摘要
Abstract: Cancer is a significant health challenge worldwide, causing social and economic burdens. Despite advancements in medicine, it remains a leading cause of death and is projected to increase by 2040. While conventional treatments like surgery, radiation, and chemotherapy are effective, they often have severe side effects. CAR T-cell (chimeric antigen receptor T-cell) treatment is a novel immunotherapy method personalized to the patient's immune system and directly targets cancer cells. It originated in the 1980s, and advancements have made it more effective. However, challenges remain, such as severe side effects, high costs, and manufacturing variability. Despite these challenges, the treatment with CAR T-cells has shown remarkable success, especially in hematologic malignancies. Though it is new to solid tumours, ongoing research looks promising. CAR T-cell therapy offers hope for fightingcancer, and it stands poised to redefine cancer treatment paradigms, giving renewed optimism to patients globally.
科研通智能强力驱动
Strongly Powered by AbleSci AI